Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Feldan Therapeutics...
GSK plc is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK&rsquo...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered porta...
Certara, Inc. a global leader in model-informed drug development, announced the launch of its Non-Animal Navigator™ solution designed to help bi...
Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosim...
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment t...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that results from a Phase 3 registrational clinical study evaluating...
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...
Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...
Vantage Biosciences is a clinical-stage biotechnology company developing innovative therapies for the treatment of diabetic eye diseases. The company ...
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food a...
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a collaboration with the National Cancer Institu...
Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event ...
AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...
© 2025 Biopharma Boardroom. All Rights Reserved.
